BridgeBio Oncology Therapeutics, Inc. (BBOT)

BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company developing small-molecule medicines for cancers driven by the RAS and PI3K signaling pathways. It was originally formed as a BridgeBio Pharma affiliate and became a separate public company on Nasdaq in 2025 through a business combination with a special purpose acquisition company.

Its pipeline includes BBO-8520, a direct inhibitor of the KRAS G12C mutation designed to target both the active and inactive forms of the protein, being studied in non-small cell lung cancer; BBO-11818, a pan-KRAS inhibitor aimed at mutations such as G12D and G12V; and BBO-10203, a molecule designed to block the interaction between RAS and PI3K-alpha, studied in breast, colorectal, and lung cancers.

The company is headquartered in South San Francisco, California.